For children with severe hypertrophic cardiomyopathy caused by gain-of-function RAS/mitogen-activated protein kinase (MAPK) mutations (RASopathy), trametinib reduces mortality and morbidity.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

1Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL), Hospitalet de Llobregat, Barcelona, Spain. 2Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), ...

Affected children are born with café-au-lait spots and sometimes Lisch nodules. During adolescence and young adulthood, more than 19% of affected individuals with NF1 develop cutaneous neurofibromas ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

The future of skin cancer treatment looks even more promising. Advances in artificial intelligence (AI) are revolutionizing ...

This is the fourth FDA-approved indication for Braftovi, coming after it was cleared in combination with MEK Inhibitor Mektovi (binimetinib) for BRAF-mutated melanoma and non-small cell lung ...

an oral RAF/MEK clamp, in combination with defactinib, an oral FAK inhibitor, for the treatment of adult patients with recurrent low-grade serous ovarian cancer (LGSOC), w Shoshana Shendelman ...

In a major breakthrough, researchers in the UK have discovered a potential root cause of inflammatory bowel disease (IBD), a ...

Research has introduced daromun, therapeutic vaccines, and novel combinations for metastatic melanoma, reshaping the ...

Impact and progress Frontiers' impact Progress Report 2022 All progress reports ...